Literature DB >> 12554694

Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3' overhang specific DNA.

Mark S Eller1, Guang-Zhi Li, Reza Firoozabadi, Neelu Puri, Barbara A Gilchrest.   

Abstract

Telomere shortening induces a nonproliferative senescent phenotype, believed to reduce cancer risk, and telomeres are involved in a poorly understood manner in responses to DNA damage. Although telomere disruption induces p53 and triggers apoptosis or cell cycle arrest, the features of the disrupted telomere that trigger this response and the precise mechanism involved are poorly understood. Using human cells, we show that DNA oligonucleotides homologous to the telomere 3' overhang sequence specifically induce and activate p53 and activate an S phase checkpoint by modifying the Nijmegen breakage syndrome protein, known to mediate the S phase checkpoint after DNA damage. These responses are mediated, at least in part, by the ATM kinase and are not attributable to disruption of cellular telomeres. Based on these and earlier data, we propose that these oligonucleotides mimic a physiological signal, exposure of the telomere 3' overhang due to opening of the normal telomere loop structure, and hence evoke these protective antiproliferative responses in the absence of DNA damage or telomere disruption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554694     DOI: 10.1096/fj.02-0197com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

1.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Topical DNA oligonucleotide therapy reduces UV-induced mutations and photocarcinogenesis in hairless mice.

Authors:  David A Goukassian; Elizabeth Helms; Harry van Steeg; Conny van Oostrom; Jag Bhawan; Barbara A Gilchrest
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

3.  A role for WRN in telomere-based DNA damage responses.

Authors:  Mark S Eller; Xiaodong Liao; SuiYang Liu; Kendra Hanna; Helena Bäckvall; Patricia L Opresko; Vilhelm A Bohr; Barbara A Gilchrest
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

4.  T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells.

Authors:  Sibaji Sarkar; Douglas V Faller
Journal:  Oligonucleotides       Date:  2011-01-31

Review 5.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

6.  Integrated nanosensors to determine levels and functional activity of human telomerase.

Authors:  J Manuel Perez; Jan Grimm; Lee Josephson; Ralph Weissleder
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  [Skin aging].

Authors:  E Kohl; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2009-11       Impact factor: 0.751

8.  T-oligo as an anticancer agent in colorectal cancer.

Authors:  Luke Wojdyla; Neelu Puri; Amanda L Stone; Nan Sethakorn; Srijayaprakash B Uppada; Joseph T Devito; Marc Bissonnette
Journal:  Biochem Biophys Res Commun       Date:  2014-03-12       Impact factor: 3.575

9.  Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.

Authors:  Neelu Puri; Ryan T Pitman; Richard E Mulnix; Terrianne Erickson; Audra N Iness; Connie Vitali; Yutong Zhao; Ravi Salgia
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

10.  Telomeric DNA induces p53-dependent reactive oxygen species and protects against oxidative damage.

Authors:  Margaret S Lee; Mina Yaar; Mark S Eller; Thomas M Rünger; Ying Gao; Barbara A Gilchrest
Journal:  J Dermatol Sci       Date:  2009-11-10       Impact factor: 4.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.